XML 56 R46.htm IDEA: XBRL DOCUMENT v3.19.1
Stockholders' Equity (Deficit) (Details Textual) - USD ($)
 1 Months Ended 2 Months Ended 3 Months Ended 6 Months Ended
Dec. 12, 2018
Feb. 28, 2019
Nov. 30, 2018
Mar. 31, 2019
Mar. 31, 2019
Sep. 30, 2018
Stockholders' Deficit (Textual)            
Liability       $ 2,130,179 $ 2,130,179 $ 4,614,611
2019 Private Placement [Member]            
Stockholders' Deficit (Textual)            
Purchase agreement, description         (i) 1 share of common stock and (ii) a warrant to purchase 1 share of common stock at an initial exercise price of $3.00 per share (the “2019 Warrants”).  
Units sold under private palcemant       1,743,979 1,903,979  
Gross proceeds from private placement         $ 4,759,948  
Estimated fair value of the broker warrants to be issued         $ 179,643  
Broker warrants to be issued shares         180,658  
Fair value of warrant issued before reclassification to equity       $ 1,193,564 $ 1,301,241  
Risk free interest rate         2.50%  
Expected stock price volatility         50.60%  
Expected life of options (years)         4 years 9 months 18 days  
Expected dividend yield         0.00%  
Direct offset to proceeds from the private placement       $ 722,806 $ 812,428  
Cash commission, percentage         8.00%  
Cash commissions amounting         $ 561,294  
Exercise price, per share         $ 3.00  
Common stock purchase price, per share         10.00%  
Warrants exercisable, term       5 years 5 years  
Commission fees related to the financing         $ 71,491  
2019 Private Placement [Member] | Paulson [Member]            
Stockholders' Deficit (Textual)            
Cash commission, percentage         12.00%  
Warrants exercisable, term       5 years 5 years  
Private placement transaction, description         HRA will receive a cash commission equal to 8% of the gross proceeds from the sale of the 2019 Units sold by HRA. In addition to the brokers' commission, the Company will issue 5-year warrants to HRA to purchase an amount of Common Stock equal to 8% of the total amount of Shares sold by HRA in the 2019 Private Placement at an exercise price of $3.00 per share.  
2019 Private Placement [Member] | Warrant [Member]            
Stockholders' Deficit (Textual)            
Maximum shares issuable         4,000,000  
Maximum potential gross proceeds from financing         $ 10,000,000  
Stock unit price per unit       $ 2.50 $ 2.50  
2019 Private Placement [Member] | Warrant [Member] | Minimum [Member]            
Stockholders' Deficit (Textual)            
Broker warrants exercise price to be issued       2.75 2.75  
2019 Private Placement [Member] | Warrant [Member] | Maximum [Member]            
Stockholders' Deficit (Textual)            
Broker warrants exercise price to be issued       $ 3.00 $ 3.00  
2018 Private Placement [Member]            
Stockholders' Deficit (Textual)            
Purchase agreement, description     (i) 1 share (each, a “Share”) of common stock and (ii) a warrant to purchase 1 share of common stock at an initial exercise price of $3.00 per share (the “2018 Warrants”).      
Maximum shares issuable 615,200          
Units sold under private palcemant       0 170,000  
Gross proceeds from private placement $ 1,538,000          
Warrant issued       40,416 40,416  
Fair value of warrant issued before reclassification to equity         $ 115,674  
Risk free interest rate         2.90%  
Expected stock price volatility         49.80%  
Expected life of options (years)         4 years 7 months 6 days  
Expected dividend yield         0.00%  
Credit adjustment amount related to HRA commission       $ 24,029 $ 35,665  
Cash commission, percentage         8.00%  
Exercise price, per share         $ 3.00  
Common stock purchase price, per share         8.00%  
Warrants exercisable, term       5 years 5 years  
Liability       $ 11,085 $ 11,085  
Legal costs related to private placement issuance costs         7,340  
Acquired percentage   10.00%        
Brokerage commission         $ 17,240  
Private placement transaction, description   The Company and HRA agreed (i) to extend the Tail Period until June 30, 2019, (ii) to modify the HRA Fee so that HRA is entitled to receive a cash fee equal to 8% of the gross proceeds received by the Company from Prospects in all subsequent private placement transactions and (iii) to modify the HRA Warrants so that they are exercisable to purchase shares of Common Stock (or common stock equivalents) in an amount equal to 8% of the shares of Common Stock purchased by Prospects in subsequent private placements (collectively, the “HRA Amendments”). Upon issuance, the HRA Warrants will be immediately exercisable and expire five years from the closing of the related transaction.        
2018 Private Placement [Member] | Warrant [Member]            
Stockholders' Deficit (Textual)            
Warrant issued       221,074 221,074  
Private Placement [Member]            
Stockholders' Deficit (Textual)            
Private placement transaction, description (i) 1 share of common stock and (ii) a warrant to purchase 1 share of common stock at an initial exercise price of $3.00 per share (the "2019 Warrants"), to the New Purchasers.